Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and tolerability study of canakinumab in active systemic juvenile idiopathic arthritis
2012-003054-92Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) (2 cohorts), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability and retention rate. Started Nov 2012; status: terminated.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2012-003054-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003054-92.